Stocks-NVO-Novo-Nordisk A/S SPONS ADR

NVO Novo-Nordisk A/S SPONS ADR

136.79 4.45 (3.36%)
Delayed Prices By NASDAQ, in USD Market Closed
Invest
Invest
-0.82% Past Week
Created with Highcharts 4.2.7 /Highstock 4.2.7
Market Cap
234.25B
Day’s Range
134.80
-
137.21
52W Range
94.33
-
141.27
Volume (3M)
1.44M
Price-Earnings Ratio
39.43
Revenue
25B

Novo-Nordisk A/S SPONS ADR Latest News

View All
Pinned Post
eToro Team
🎉 Here’s a little preview introducing 16 YEARS of INVESTING on eToro 😏🤑 With love, - The eToro Team youtu.be/UFYvpJxh2qA
Like CommentShare
Show more comments2 of 65
1 reply
1 reply
null
.
Top Discussions
MarketUpdates
Edited
$NVO (Novo-Nordisk A/S SPONS ADR) Q1 2023 earnings report is expected to be released
4
MAY
REPORTS
Novo-Nordisk A/S SPONS ADR Q1 2023 earnings report is expected to be released before market open
Notify me
NVO
NVO
Novo-Nordisk A/S SPONS ADR
136.79
4.45
(3.36%)
Trade
NVO
Novo-Nordisk A/S SPONS ADR
136.52
4.45 (3.36%)
Trade
MarketUpdates
$NVO (Novo-Nordisk A/S SPONS ADR) Q1 2023 earnings report is expected to be released
Antonio Jimenez Torres
$NVO (Novo-Nordisk A/S SPONS ADR) Featured headlines 02/01/2023 - Novo Nordisk will launch a new share buyback program worth 28,000 million Danish crowns, in exchange for 4,100 million dollars, at current prices 1.30% of the market capitalization. - Novo Nordisk forecasts sales growth of 13-19% in... Show More
Like CommentShare
null
.
Fabian Schneider
𝙉𝙤𝙫𝙤 𝙉𝙤𝙧𝙙𝙞𝙨𝙠 𝙌𝙪𝙖𝙧𝙩𝙚𝙧𝙡𝙮 𝙛𝙞𝙜𝙪𝙧𝙚𝙨: Operating profit increased by 28% in Danish kroner and by 15% at constant exchange rates (CER) to DKK 74.8 billion. Sales in North America Operations increased by 35% in Danish kroner (21% at CER), and sales in International Operations increased... Show More
Like CommentShare
null
.
Fabian Schneider
I remember the last quarterly figures where Novo fell by 6% the day before, for no real reason. I expect good numbers tomorrow. Expectations are high, but Novo is a first class company $NOVO-B.CO (Novo Nordisk B A/S) $NVO (Novo-Nordisk A/S SPONS ADR)
Like CommentShare
null
.

About Novo-Nordisk A/S SPONS ADR

Novo Nordisk A/S, a healthcare company based in Bagsværd, Denmark, researches, develops, and markets pharmaceuticals. The company was founded in 1923. Novo Nordisk operates internationally through its worldwide locations. The company operates through two segments: the Diabetes and Obesity segment provides products such as insulin, and the Biopharmaceuticals segment focuses on products such as growth disorder and hormone replacement therapies. The company is currently collaborating with Lund University regarding Parkinson’s disease research. Novo Nordisk is listed on the NYSE under the NVO stock ticker. Add this instrument to your eToro watchlist to receive updates and news on the NVO share price.
54.3K
Employees
Bagsværd, Capital Region, US
HQ
1931
Founded
Lars Fruergaard Jørgensen, MBA
CEO
Show More

Upcoming Earnings

4
MAY
REPORTS
Novo-Nordisk A/S SPONS ADR Q1 2023 earnings report is expected to be released before market open

People Also Bought